John L. Wallace
John L. Wallace, Ph.D. is the founder and Chief Scientific Officer at Antibe Therapeutics Inc. He is an adjunct professor in the Faculty of Medicine at the University of Calgary and in the Department of Pharmacology and Toxicology at the University of Toronto.
John L. Wallace, Ph.D. is the founder and Chief Scientific Officer at Antibe Therapeutics Inc. He is an adjunct professor in the Faculty of Medicine at the University of Calgary and in the Department of Pharmacology and Toxicology at the University of Toronto.
Articles: John L. Wallace
Global Pharma has Reinvented R&D: Will Canadian Start-Ups Lead the Next Phase?
Canada / John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising North American start-up with a new Parkinson’s disease drug, was recently sold to Germany’s Bayer at a $1 billion valuation. Bayer also acquired BlueRock’s innovative…
Latest Report
